InspireMD

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InspireMD reports strong Q1 performance, eyes future growth opportunities

InspireMD's Q1 2024 showcased revenue growth and promising trial results, but challenges in gross profit and rising expenses. Strategic agreements and upcoming product approvals present opportunities for future growth and innovation.

InspireMD reports revenue growth, faces cost challenges, eyes U.S. launch

InspireMD's Q2 2024 performance reflects revenue growth but challenges in managing costs and achieving profitability.
The company's strengths lie in groundbreaking clinical outcomes, successful financings, and preparations for a U.S. commercial launch.
While facing cost and financial challenges, InspireMD has opportunities to drive market expansion, innovation, and capitalize on its strong cash position.
Balancing growth initiatives with cost control will be key for InspireMD's sustainable financial success and market competitiveness.

InspireMD reports 16% revenue growth in Q3 2024 earnings call

InspireMD's Q3 performance reflects revenue growth but challenges in profitability due to cost dynamics.
The company's strategic strengths lie in international sales, product innovation, and U.S. market focus.
Opportunities include FDA approvals, market expansion, and strong financial position for growth initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Miami, FL.

Development of SwitchGuard™ consistent with Company's mission to uniquely support both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures with best-in-class carotid implant and platform Development of SwitchGuard™ consistent with Company's mission to uniquely support both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures with best-in-class carotid implant and platform

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

InspireMD's (NSPR) CE Mark Recertification under MDR is likely to help the company boost the CGuard EPS for carotid artery revascularization care along with advancing with new products.

InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS

TEL AVIV, Israel and MIAMI, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that it has received CE Mark recertification under the European Union's new Medical Device Regulation (MDR) regulatory framework. MDR replaced the previous MDD framework, which had governed the approval and marketing of medical devices in the EU until May of 2021.

InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework

Appointment brings more than 30 years of medical technology general management and commercial leadership experience to the InspireMD team

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

Reflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the treatment of carotid artery disease and the prevention of stroke Reflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the treatment of carotid artery disease and the prevention of stroke

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

TEL AVIV, Israel and MIAMI, Nov. 27, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the company has entered into a strategic agreement with the Jacobs Institute at the State University of New York at Buffalo, and Dr. Adnan Siddiqui, Vice-Chairman and Professor of Neurosurgery, to execute an Early Feasibility Study (EFS) evaluating the CGuard EPS carotid stent to treat severe carotid stenosis or occlusion, in conjunction with thrombectomy, in patients presenting with acute ischemic stroke and tandem lesions. Marvin Slosman, chief executive officer of InspireMD, stated, “This Early Feasibility Study provides the appropriate platform for our investment in this indication to address Carotid lesions in acute stroke settings and reinforces our commitment to the neuro community, as we aim to demonstrate that CGuard EPS is optimally designed with a low metal surface and MicroNet™ mesh covering for superior embolic protection during these acute events.

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

InspireMD, Inc. (NSPR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -24.61% in 4 Weeks, Here's Why InspireMD, Inc. (NSPR) Looks Ripe for a Turnaround

InspireMD Inc. (NASDAQ:NSPR ) Q3 2023 Results Earnings Conference Call November 6, 2023 8:30 AM ET Company Participants Charles Padala - Investor Relations, LifeSci Advisors Marvin Slosman - President, CEO and Director Craig Shore - Chief Financial Officer Conference Call Participants Adam Maeder - Piper Sandler Benjamin Haynor - Alliance Global Partners Operator Good morning. And welcome to the InspireMD Third Quarter of 2023 Earnings Call.

InspireMD Inc. (NSPR) Q3 2023 Earnings Call Transcript

- Presented positive 30-day follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial demonstrating an overall major adverse events rate (DSMI) of 0.95% from procedure through 30 days at the Vascular InterVentional Advances Annual Meeting (VIVA23) –

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

TEL AVIV, Israel and MIAMI, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke, today announced that the Marvin Slosman, Chief Executive Officer, will participate in three upcoming investor conferences in November:

InspireMD to Participate in Upcoming November Investor Conferences

Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure

InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23

-Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Oct. 30, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report third quarter 2023 financial results on Monday, November 6th, 2023, before the financial markets open.

InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th

Provides additional treatment options for patients and treating physicians; likely expands CAS addressable market Potentially accelerates conversion of carotid interventions from surgery (carotid endarterectomy) to minimally invasive CAS and TCAR procedures InspireMD advancing both CAS and TCAR stent delivery platforms along U.S. and E.U. regulatory pathways leveraging proven CGuard EPS stent system TEL AVIV, Israel and MIAMI, Oct. 12, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced its support for the Centers for Medicare and Medicaid Services (CMS) final National Coverage Determination (NCD) which expands coverage of carotid artery stenting (CAS) and transcarotid artery revascularization (TCAR) to include both asymptomatic and standard risk patients.

InspireMD Supports CMS' Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients

Announces hiring of Patrick Verta, MD, as Executive VP of Clinical and Medical Affairs Cheryl Tal joins as VP of Quality Assurance and Regulatory Affairs Shane Gleason, current General Manager of North America & VP of Global Marketing, promoted to Chief Commercial Officer Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) TEL AVIV, Israel and MIAMI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced senior leadership additions and changes intended to support the company's commercial growth initiatives, including potential approval of the CGuard Prime stent platform in the U.S., development of new stent delivery systems, and growth in existing approved territories outside of the U.S. The company announced today that it has hired Patrick Verta, MD, as Executive Vice President of Clinical and Medical Affairs and Cheryl Tal as Vice President of Quality Assurance and Regulatory Affairs. In addition, Shane Gleason, who previously served as InspireMD's General Manager of North America and VP of Global Marketing, has been promoted to Chief Commercial Officer.

InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives

TEL AVIV, Israel, and MIAMI, Aug. 31, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract detailing upcoming 30-day results from its C-Guardians U.S. IDE clinical trial has been accepted for presentation as a late-breaking clinical trial at the Vascular InterVentional Advances Annual Meeting (VIVA23), which is being held October 30 through November 2 in Las Vegas.

InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23

InspireMD Inc. (NASDAQ:NSPR ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Glenn Garmont - IR Marvin Slosman - President, CEO and Director Amir Kohen - Interim CFO, Secretary and Treasurer Conference Call Participants Adam Maeder - Piper Sandler Benjamin Haynor - Alliance Global Partners Operator Good morning, and welcome to the InspireMD Second Quarter 2023 Earnings Call. Currently all participants are in a listen-only mode.

InspireMD Inc. (NSPR) Q2 2023 Earnings Call Transcript

- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront – - Completed enrollment in the C-Guardians US IDE trial; on track to announce primary and secondary endpoints and, if successful, submit PMA application in H2 2024 – - Generated Q2 2023 CGuard EPS revenue of $1.6 million, an increase of nearly 10% over Q2 2022 – -- Management to host investor conference call today, August 8, at 8:30am ET -- TEL AVIV, Israel, and MIAMI, Aug. 08, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke today announced financial and operating results for the second quarter ended June 30, 2023. Second Quarter 2023 and Recent Developments: Successfully completed a transformational private placement of common shares, prepaid warrants and warrants for up to $113.6 million in gross proceeds, including $42.2 million upfront and additional proceeds of up to $71.4 million upon exercise of milestone-driven warrants.

InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2023 financial results on Tuesday, August 8thth, 2023, before the financial markets open.

InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th

Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system Study also included first-in-human cases treated with CGuard Prime CAS stent delivery platform Company anticipates study results and Premarket Approval (PMA) submission in H2 2024, potential U.S. approval in H1 2025 TEL AVIV, Israel, June 26, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it completed enrollment of its ongoing C-Guardians U.S. Investigational Device Exemption (IDE) clinical trial, designed to support potential U.S. marketing approval of the CGuard Prime EPS stent system. Marvin Slosman, chief executive officer of InspireMD, stated, “The completion of enrollment in our IDE trial is a significant milestone and brings us one step closer to potential U.S. approval of the CGuard Prime EPS stent system.

InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial

TEL AVIV, Israel and MIAMI, May 18, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that, in connection with the appointment of Shane Gleason as General Manager of North America and VP of Global Marketing in February 2023, InspireMD granted Mr. Gleason 256,450 shares of restricted stock and stock options to purchase 85,480 shares of InspireMD's common stock. The grant of restricted stock and stock options was approved by the Compensation Committee of InspireMD's Board of Directors and was granted outside of InspireMD's 2021 Equity Compensation Plan, with a grant date of May 17, 2023, as an inducement material to Mr. Gleason entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).

InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Start Time: 08:30 January 1, 0000 8:53 AM ET InspireMD, Inc. (NASDAQ:NSPR ) Q1 2023 Earnings Conference Call May 16, 2023, 08:30 AM ET Company Participants Marvin Slosman - CEO Craig Shore - CFO Glenn Garmont - IR, LifeSci Advisors Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Good day, and welcome to the InspireMD First Quarter 2023 Earnings Call. All participants will be in listen-only mode.

InspireMD, Inc. (NSPR) Q1 2023 Earnings Call Transcript

- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront -

InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update

Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members

InspireMD Announces Private Placement of Up to $113.6 Million

- Conference call and webcast to be held at 8:30 a.m. EDT - TEL AVIV, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today that it will host its conference call and webcast to review first quarter 2023 financial and operating results on Tuesday, May 16th, 2023, before the markets open.

InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, May 05, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will now report first quarter 2023 financial results on Monday, May 15th, 2023.

News for InspireMD Stock (NSPR)